Mark Schoenberg

This profile gathers the share dealings of Mark Schoenberg in UroGen Pharma Ltd., where the filings describe the role as senior executive. We count 30 filings; the first trade dates from 30 April 2021 and the latest from 8 September 2026.

Both buying and selling appear: 1 purchase worth €1,851, against 8 sales worth €3.4M. Sales outweigh purchases by €3.4M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 21 option exercises. In 2026 alone, the filings show no purchases and 4 sales.

The newest entry dates from 9 September 2026: an option exercise, in UroGen Pharma Ltd. The clock since the last published purchase (19 November 2021) now reads 1,794 days. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.